Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EQEVI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CBT-3112
|
|||||
| Synonyms |
DCLK1 targeting paclitaxel based ADC (Coare Biotechnology); CBT3112; CBT 3112
Click to Show/Hide
|
|||||
| Organization |
COARE Biotechnology Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Colorectal cancer [ICD11:2B91]
Clinical candidate
Pancreatic cancer [ICD11:2C10]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Serine/threonine-protein kinase DCLK1 (DCLK1)
|
Antigen Info | ||||
| Payload Name |
Paclitaxel
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.